HDAC9 and neoplasm: These data suggest that blocking HDAC or tyrosine kinase cell-cycle progression regulator WEE1 may provide therapeutic vulnerabilities through cytotoxic effects and might also restore tumor immunogenicity, increasing the effects of immune checkpoint inhibitors in desert-like WTs.